Objective To analyze the incidence and mortality of pancreatic cancer in 2022 globally and in China based on the Global Cancer Statistics 2022 published by the International Agency for Research on Cancer, considering characteristics such as gender, age, and human development index (HDI). Methods Pancreatic cancer data from 185 countries and regions were sourced from the GLOBOCAN 2022 database, and HDI data were compiled based on the Human Development Report 2022 published by the United Nations Development Programme.Cancer data were stratified by age, gender, and HDI to describe the prevalence of pancreatic cancer globally and in China.Pearson correlation analysis was used to evaluate the correlation of standardized incidence rate (SIR), standardized mortality rate (SMR), and mortality-to-incidence ratio (M/I) with HDI. Results In 2022, the number of pancreatic cancer incident cases worldwide was 510 992, ranking 12^th among all cancer incidents, with an SIR of 4.7 per 100 000 (ranking 15^th).The number of pancreatic cancer deaths globally was 467 409, ranking 6^th among all cancer deaths, with an SMR of 4.2 per 100 000 (ranking 9^th).In China, the number of pancreatic cancer incident cases was 118 672 (ranking 10^th among all cancer incidents), accounting for 23.22% of the global pancreatic cancer incidents, with an SIR of 4.4 per 100 000 (ranking13^rd).The number of pancreatic cancer deaths in China was 106 295 (ranking 6^th among all cancer deaths), accounting for 22.74% of the global pancreatic cancer deaths, with an SMR of 3.9 per 100 000 (ranking 8^th).The incidence, mortality, SIR, and SMR in males were higher than those in females both globally and in China.SIR and SMR were positively correlated with HDI (r=0.77 and 0.77, both P＜0.001), while M/I was negatively correlated with HDI (r=-0.43, P＜0.001).The incidence, mortality, SIR and SMR of pancreatic cancer showed an increasing trend with age, and rapidly increased from 45-49 years old. Conclusion The disease burden of pancreatic cancer is serious globally and in China.The incidence and mortality of pancreatic cancer show an upward trend with age, and they are higher in males than in females.HDI is positively correlated with SIR and SMR of pancreatic cancer, while negatively correlated with M/I.